CE Melphalan meets Phase 2 primary endpoint

Spectrum Pharmaceuticals' (SPPI) conditioning treatment in autologous transplants in multiple myeloma, Captisol-enabled (propylene glycol-free) Melphalan (CE Melphalan) meets its primary endpoint of determining the overall safety and toxicity profile in multiple myeloma patients receiving 200mg/m2 of CE Melphalan as myeloablative therapy prior to autologous stem cell transplantation.

Propylene glycol is associated with undesirable renal and cardiac side effects that limit the ability to deliver higher doses of therapeutic compounds.

A previous clinical trial established bioequivalence to the currently-available IV formulation of melphalan.

The company plans to file an NDA in Q3.

The FDA granted Orphan Drug Designation to the product for this indication.

Comments (1)
  • Patent News
    , contributor
    Comments (1475) | Send Message
    will it make it to 8 today?


    market is choppy today but loading it when low.
    23 Apr 2014, 09:39 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs